Likewise, anti–Tumor Necrosis Factor-alpha (anti–TNF-α) and anti–Interleukin-1 (anti–IL-1) therapies, which neutralize key cytokines in the early storm, showed limited efficacy and potential harm in broad sepsis populations [30]. The gene discussed is IL1B; the disease is Sepsis.